Orion Pharma (UK) Limited

Oaklea Court, 22 Park Street, Newbury, Berkshire, RG14 1EA
Telephone: +44 (0)1635 520 300
Fax: +44 (0)1635 580 180
Medical Information e-mail: medicalinformation@orionpharma.com
Out of Hours Telephone: +44 (0)1635 520 300

Patient Information Leaflet last updated on the eMC: 02/09/2011
PIL Eldepryl

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 02/09/2011 and displayed until Current
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to side-effects
  • Change to drug interactions
  • Change to information about drinking alcohol
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
Updated on 17/03/2011 and displayed until 02/09/2011
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 30/03/2010 and displayed until 17/03/2011
Reasons for adding or updating:
  • Change/addition of instructions for reconstitution and/ or administration
  • Change to warnings or special precautions for use
  • Change to drug interactions
Updated on 10/03/2009 and displayed until 30/03/2010
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 25/09/2006 and displayed until 10/03/2009
Reasons for adding or updating:
  • Change to date of revision
Updated on 10/12/2003 and displayed until 25/09/2006
Reasons for adding or updating:
  • Update to PIL
Updated on 22/01/2003 and displayed until 10/12/2003
Reasons for adding or updating:
  • Update to PIL
Updated on 27/11/2002 and displayed until 22/01/2003
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but new to the eMC

Active Ingredients/Generics

 
   selegiline hydrochloride